World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
105
Citations
56286
World Ranking
6675
National Ranking
221

Nicoletta Colombo publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Nicoletta Colombo sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 781 publications — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Nicoletta Colombo D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Nicoletta Colombo sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 105 D-Index — 67th percentile

67% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Nicoletta Colombo is affiliated with the University of Milano-Bicocca in Italy, focusing primarily on medical research. Their work spans multiple fields within medicine, with a concentrated interest in hematology, reproductive medicine, molecular biology, public health, environmental and occupational health, and oncology.

The scientist's research topics include:

  • Acute Myeloid Leukemia Research
  • Ovarian cancer diagnosis and treatment
  • Acute Lymphoblastic Leukemia research
  • Chronic Myeloid Leukemia Treatments
  • Multiple Myeloma Research and Treatments
  • Histone Deacetylase Inhibitors Research
  • Immune Cell Function and Interaction

Nicoletta Colombo has contributed to several recent publications, among them:

  • "Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden" (2020, Cancers)
  • "Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation" (2021, European Journal Of Haematology)
  • "Primary versus interval cytoreductive surgery in patients with rare epithelial or non-epithelial ovarian cancer" (2025, International Journal of Gynecological Cancer)
  • "ADAGIO: A phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma." (2021, Journal of Clinical Oncology)
  • "Textbook oncologic outcome is an easy-to-use composite quality measure that is strongly associated with survival in advanced-stage ovarian cancer" (2024, Gynecologic Oncology)

Their frequent co-authors include:

  • Paola Minetto
  • Fabio Guolo
  • Michele Cea
  • Roberto M. Lemoli
  • Elisabetta Tedone

The main venues in which Nicoletta Colombo publishes research are:

  • Blood
  • International Journal of Gynecological Cancer
  • HemaSphere
  • Gynecologic Oncology
  • Cancers

This profile reflects a detailed focus on both hematologic malignancies and gynecological cancers, demonstrating a multidisciplinary approach to medical research and clinical outcomes evaluation.

Best Publications

  • ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.

    Nicoletta Colombo;Carien Creutzberg;Frederic Amant;Tjalling Bosse

  • Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Kathleen Moore;Nicoletta Colombo;Giovanni Scambia;Byoung Gie Kim

  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    Eric Pujade-Lauraine;Jonathan A Ledermann;Frédéric Selle;Val Gebski

  • Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

    MK Parmar;JA Ledermann;N Colombo;Bois A Du

  • Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

    Isabelle Ray-Coquard;Patricia Pautier;Sandro Pignata;David Pérol

  • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Robert L Coleman;Amit M Oza;Domenica Lorusso;Carol Aghajanian

  • ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.

    Nicole Concin;Xavier Matias-Guiu;Ignace Vergote;David Cibula

  • Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    J.A. Ledermann;F.A. Raja;C. Fotopoulou;A. Gonzalez-Martin

  • ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

    N. Colombo;C. Sessa;A. du Bois;J. Ledermann

  • THE EFFECT OF DEBULKING SURGERY AFTER INDUCTION CHEMOTHERAPY ON THE PROGNOSIS IN ADVANCED EPITHELIAL OVARIAN CANCER. GYNECOLOGICAL CANCER COOPERATIVE GROUP OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER

    Maria E.L. van der Burg;Mat van Lent;Marc Buyse;Anna Kobierska

  • Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup

    Michael A. Bookman;Mark F. Brady;William P. McGuire;Peter G. Harper

  • Ovarian Cancer: Screening, Treatment, and Follow-up

    Vicki Seltzer;Bruce H. Drukker;Brenda W. Gillespie;Lynn M. Gossfeld

  • European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

    E A Eisenhauer;W W ten Bokkel Huinink;K D Swenerton;L Gianni

  • Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    N. Colombo;N. Colombo;S. Carinelli;A. Colombo;C. Marini

  • Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial

    M. K B Parmar;M. Adams;M. Balestrino;K. Bertelsen

  • Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

    Nicoletta Colombo;Coraline Dubot;Domenica Lorusso;M Valeria Caceres

  • Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    N. Colombo;E. Preti;F. Landoni;S. Carinelli

  • Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

    Amit M Oza;David Cibula;Ana Oaknin Benzaquen;Christopher Poole

  • Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

    U.A. Matulonis;R. Shapira-Frommer;A.D. Santin;A.S. Lisyanskaya

  • European-Canadian randomized trial of Paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

    Elizabeth A. Eisenhauer;Wim W. ten Bokkel Huinink;Kenneth D. Swenerton;Luca Gianni

Frequent Co-Authors

Giovanni Scambia
Giovanni Scambia Catholic University of the Sacred Heart
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre
Ana Oaknin
Ana Oaknin Vall d'Hebron Hospital Universitari
Sandro Pignata
Sandro Pignata National Cancer Institute
Jonathan A. Ledermann
Jonathan A. Ledermann University College London
Carol Aghajanian
Carol Aghajanian Memorial Sloan Kettering Cancer Center
Michael Friedlander
Michael Friedlander University of New South Wales
Valter Torri
Valter Torri Mario Negri Institute for Pharmacological Research
Domenica Lorusso
Domenica Lorusso Catholic University of the Sacred Heart

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine opens the door to a variety of educational and professional paths beyond a traditional medical degree. For those interested in healthcare leadership, pursuing one of the affordable online mha programs can prepare you for management roles in hospitals, clinics, and other healthcare facilities.

Advanced practice nurses looking to expand their expertise may be interested in exploring the cheapest dnp online programs. These programs offer flexibility without compromising on curriculum quality, helping nurses achieve the highest levels of clinical practice.

Those focused on the pharmaceutical side of healthcare may look into online pharmacy programs, which can lead to rewarding careers in both patient care and research.

If you are interested in the intersection of technology and healthcare, an online bachelor's in health information management can equip you with the skills needed to manage critical medical data and support healthcare operations efficiently.

Best Scientists Citing Nicoletta Colombo

Trending Scientists

Recently Published Articles